IDENIX PHARMACEUTICALS INC
IDIX
IDIX was delisted on the 5th of August, 2014.
131 hedge funds and large institutions have $2.78B invested in IDENIX PHARMACEUTICALS INC in 2014 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 16 closing their positions.
300% more capital invested
Capital invested by funds: $696M → $2.78B (+$2.09B)
219% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 16
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
36% more funds holding
Funds holding: 96 → 131 (+35)
12% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 34
41% less call options, than puts
Call options by funds: $29.7M | Put options by funds: $50.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.3M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$31M |
| 3 |
Morgan Stanley
New York
|
+$15.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$15.3M |
| 5 |
Barclays
London,
United Kingdom
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$71.1M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$58.8M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$31.8M |
| 4 |
State Street
Boston,
Massachusetts
|
-$18.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.1M |
IDIX Hedge Fund Activity: Q2 2014 in Review
131 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in IDENIX PHARMACEUTICALS INC (IDIX) for Q2 2014, worth a combined $2.78B — up 300% from $696M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new IDIX positions and 16 closed out — a net gain of 35 holders — while 38 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $49.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $71.1M.
- 131 institutional investors held IDENIX PHARMACEUTICALS INC (IDIX) as of Q2 2014, up from 96 in Q1 2014.
- Funds reported $2.78B of IDENIX PHARMACEUTICALS INC stock for Q2 2014, up 300% quarter-over-quarter.
- 51 funds opened new IDENIX PHARMACEUTICALS INC positions in Q2 2014 and 16 closed out, a net change of +35 holders.
- The largest IDENIX PHARMACEUTICALS INC buyer in Q2 2014 was Fidelity Investments, an estimated $49.3M added.
- The largest IDENIX PHARMACEUTICALS INC seller in Q2 2014 was T. Rowe Price Associates, an estimated $71.1M sold.
Based on aggregated 13F filings for Q2 2014.